Evidence map›Paper›PMID 35601969›Full record

ArticleNeuro-oncology practice2022

[

Ramon F Barajas, Prakash Ambady, Jeanne Link, Kenneth A Krohn, Ahmed Raslan, Nadine Mallak, Randy Woltjer, Leslie Muldoon, Edward A Neuwelt

Open access · greenAbstract readCase Reports
In one paragraph

Article in Neuro-oncology practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 7 citations in OpenAlex.

  1. Molecular Brain Tumor Imaging Beyond [AJR. American journal of roentgenology · 2026
    Review
  2. Neuromolecular medicine · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Ramon F BarajasDepartment of Radiology, Neuroradiology Section, Oregon Health & Science University, Portland Oregon, USA.ORCID https://orcid.org/0000-0001-5093-4168
Prakash AmbadyNeuro-Oncology and Blood-Brain Barrier Program, Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA.
Jeanne LinkCenter for Radiochemistry Research, Oregon Health & Science University, Portland, Oregon, USA.
Kenneth A KrohnCenter for Radiochemistry Research, Oregon Health & Science University, Portland, Oregon, USA.
Ahmed RaslanDepartment of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, USA.ORCID https://orcid.org/0000-0002-5622-1115
Nadine MallakAdvanced Imaging Research Center, Oregon Health & Science University, Portland Oregon, USA.
Randy WoltjerDepartment of Pathology, Oregon Health & Science University, Portland, Oregon, USA.
Leslie MuldoonNeuro-Oncology and Blood-Brain Barrier Program, Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA.
Edward A NeuweltNeuro-Oncology and Blood-Brain Barrier Program, Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA.
Oregon Health & Science University · US

Funding

Oregon Clinical and Translational Research Institute KL2 SupplementKL2TR002370 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Catherine Lee Hough · 2017 to 2026
$10.1M
Defining the Hypoxic Immunosuppressive Microenvironment as a Biomarker of Therapy Efficacy in Glioblastoma Using Iron Oxide Enhanced FMISO PET/MRIK08CA237809 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI BARAJAS, RAMON FRANCISCO · 2020 to 2024
$1.2M
NCATS NIH HHS KL2 TR002370NCI NIH HHS K08 CA237809NCI NIH HHS L30 CA220897
6 · The paper itself

Abstract

Response assessment after immunotherapy remains a major challenge in glioblastoma due to an expected increased incidence of pseudoprogression. Gadolinium-enhanced magnetic resonance imaging (MRI) is the standard for monitoring therapeutic response, however, is markedly limited in characterizing pseudoprogression. Given that hypoxia is an important defining feature of glioblastoma regrowth, we hypothesized that [

Indexed as

FMISOglioblastomapembrolizumabpseudoprogressionRANO

Identifiers

PMID35601969
PMCPMC9113243
OpenAlexW4220896331

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.